2024

Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study
Anastasopoulou S, Swann G, Andres-Jensen L, Attarbaschi A, Barzilai-Birenboim S, Erdelyi D, Escherich G, Hamadeh L, Harila A, Lopez-Lopez E, McGowan S, Möricke A, Putti C, Sagi J, Schmiegelow K, Ullrich N, van der Sluis I, Wahid Q, Winick N, Sramkova L, Zalcberg Y, Zapotocka E, Bhojwani D, Halsey C
BRIT J HAEMATOL. 2024;205(4):1450-1459.

No clear benefit of preventive cranial radiotherapy in childhood Philadelphia-positive acute lymphoblastic leukemia: a retrospective analysis of the EsPhALL2010 study
Conter V, Valsecchi M, De Lorenzo P, Gandemer V, Heyman M, Saha V, Diaz P, Li C, Attarbaschi A, Escherich G, Stary J, Schrappe M, Pieters R, Cario G, Biondi A
HAEMATOLOGICA. 2024;109(11):3766-3770.

Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial
Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G, Bochennek K, Gruhn B, Lang P, Rohde M, Debatin K, Steinbach D, Beilken A, Ladenstein R, Spachtholz R, Heiss P, Hellwig D, Tröger A, Koller M, Menhart K, Riemenschneider M, Zoubaa S, Kietz S, Jakob M, Sommer G, Heise T, Hundsdörfer P, Kühnle I, Dilloo D, Schönberger S, Schwabe G, von Luettichau I, Graf N, Schlegel P, Frühwald M, Jorch N, Paulussen M, Schneider D, Metzler M, Leipold A, Nathrath M, Imschweiler T, Christiansen H, Schmid I, Crazzolara R, Niktoreh N, Cario G, Faber J, Demmert M, Babor F, Fröhlich B, Bielack S, Bernig T, Greil J, Eggert A, Simon T, Foell J
LANCET ONCOL. 2024;25(7):922-932.

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies
Elitzur S, Shiloh R, Loeffen J, Pastorczak A, Takagi M, Bomken S, Baruchel A, Lehrnbecher T, Tasian S, Abla O, Arad-Cohen N, Astigarraga I, Ben-Harosh M, Bodmer N, Brozou T, Ceppi F, Chugaeva L, Dalla Pozza L, Ducassou S, Escherich G, Farah R, Gibson A, Hasle H, Hoveyan J, Jacoby E, Jazbec J, Junk S, Kolenova A, Lazic J, Lo Nigro L, Mahlaoui N, Miller L, Papadakis V, Pecheux L, Pillon M, Sarouk I, Stary J, Stiakaki E, Strullu M, Tran T, Ussowicz M, Verdu-Amoros J, Wakulinska A, Zawitkowska J, Stoppa-Lyonnet D, Taylor A, Shiloh Y, Izraeli S, Minard-Colin V, Schmiegelow K, Nirel R, Attarbaschi A, Borkhardt A
BLOOD. 2024;144(11):1193-1205.

Reintegration into school, kindergarten and work in families of childhood cancer survivors after a family-oriented rehabilitation program
Inhestern L, Nasse M, Krauth K, Kandels D, Rutkowski S, Escherich G, Bergelt C
FRONT PEDIATR. 2024;12:1288567.

Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction
Moorman A, Enshaei A, Murdy D, Joy M, Boer J, den Boer M, Pieters R, de Haas V, Horstmann M, Escherich G, Johansson B, Marquart H, Schmiegelow K, Hancock J, Moppett J, Heyman M
LEUKEMIA. 2024;38(9):2023-2026.

ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
Østergaard A, Fiocco M, de Groot-Kruseman H, Moorman A, Vora A, Zimmermann M, Schrappe M, Biondi A, Escherich G, Stary J, Imai C, Imamura T, Heyman M, Schmiegelow K, Pieters R
LEUKEMIA. 2024;38(7):1477-1487.

Addressing gaps and enhancing experiences in support services for families of pediatric cancer survivors
Paul V, Inhestern L, Sigmund D, Winzig J, Rutkowski S, Escherich G, Bergelt C
PEDIATR RES. 2024 [Epub ahead of print].

The needs of families of pediatric cancer survivors: challenges and developments in psychosocial support services
Paul V, Inhestern L, Sigmund D, Winzig J, Rutkowski S, Escherich G, Bergelt C
PEDIATR RES. 2024 [Epub ahead of print].

An artificial intelligence-assisted clinical framework to facilitate diagnostics and translational discovery in hematologic neoplasia
Tang M, Antić Ž, Fardzadeh P, Pietzsch S, Schröder C, Eberhardt A, van Bömmel A, Escherich G, Hofmann W, Horstmann M, Illig T, McCrary J, Lentes J, Metzler M, Nejdl W, Schlegelberger B, Schrappe M, Zimmermann M, Miarka-Walczyk K, Pastorczak A, Cario G, Renard B, Stanulla M, Bergmann A
EBIOMEDICINE. 2024;104:105171.

Pediatric T-cell lymphoblastic lymphomas but not leukemias harbor TRB::NOTCH1 fusions with unfavorable outcome
Te Vrugt M, Wessolowski J, Randau G, Alfert A, Mueller S, Scholten K, Sopalla C, Lanvers-Kaminsky C, Hotfilder M, Lamp F, Damm-Welk C, Luedersen J, Escherich G, Zur Stadt U, Behrmann L, Woessmann W, Oschlies I, Marzi M, Zimmermann M, Burkhardt B
BLOOD. 2024;144(13):1412-1417.

Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations
van Outersterp I, Boer J, van de Ven C, Reichert C, Boeree A, Kruisinga B, de Groot-Kruseman H, Escherich G, Sijs-Szabo A, Rijneveld A, den Boer M
BLOOD ADV. 2024;8(8):1835-1845.

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain
van Outersterp I, Tasian S, Reichert C, Boeree A, de Groot-Kruseman H, Escherich G, Boer J, den Boer M
BLOOD. 2024;143(21):2178-2189.

A Multimodal Lifestyle Psychosocial Survivorship Program in Young Cancer Survivors: The CARE for CAYA Program-A Randomized Clinical Trial Embedded in a Longitudinal Cohort Study
von Grundherr J, Elmers S, Koch B, Hail L, Mann J, Escherich G, Bergelt C, Samland L, Jensen W, Vettorazzi E, Stark M, Valentini L, Baumann F, Singer S, Reer R, Beller R, Calaminus G, Faber J, Classen C, Gebauer J, Hilgendorf I, Koehler M, Puzik A, Salzmann N, Sander A, Schiffmann L, Sokalska-Duhme M, Schuster S, Kock-Schoppenhauer A, Bokemeyer C, Sinn M, Stein A, Dwinger S, Salchow J
JAMA NETW OPEN. 2024;7(3):e242375.

And what about today? Burden and support needs of adolescent childhood cancer survivors in long-term follow-up care-A qualitative content analysis
Winzig J, Inhestern L, Sigmund D, Paul V, Hail L, Rutkowski S, Escherich G, Bergelt C
CHILD CARE HLTH DEV. 2024;50(1):e13207.

Exploring the perspective of adolescent childhood cancer survivors on follow-up care and their concerns regarding the transition process-A qualitative content analysis
Winzig J, Inhestern L, Sigmund D, Paul V, Hail L, Rutkowski S, Escherich G, Bergelt C
CANCER MED-US. 2024;13(10):.

2023

Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study
Attarbaschi A, Möricke A, Harrison C, Mann G, Baruchel A, De Moerloose B, Conter V, Devidas M, Elitzur S, Escherich G, Hunger S, Horibe K, Manabe A, Loh M, Pieters R, Schmiegelow K, Silverman L, Stary J, Vora A, Pui C, Schrappe M, Zimmermann M
J CLIN ONCOL. 2023;41(7):1404-1422.

Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma
Au-Yeung R, Padilla L, Zimmermann M, Reinke S, Oschlies I, Escherich G, Woessmann W, Burkhardt B, Klapper W
LEUKEMIA. 2023;37(2):488-491.

Long-Term Antibody Response to SARS-CoV-2 in Children
Dunay G, Barroso M, Woidy M, Danecka M, Engels G, Hermann K, Neumann F, Paul K, Beime J, Escherich G, Fehse K, Grinstein L, Haniel F, Haupt L, Hecher L, Kehl T, Kemen C, Kemper M, Kobbe R, Kohl A, Klokow T, Nörz D, Olfe J, Schlenker F, Schmiesing J, Schrum J, Sibbertsen F, Stock P, Tiede S, Vettorazzi E, Zazara D, Zapf A, Lütgehetmann M, Oh J, Mir T, Muntau A, Gersting S
J CLIN IMMUNOL. 2023;43(1):46-56.

EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy
Elitzur S, Vora A, Burkhardt B, Inaba H, Attarbaschi A, Baruchel A, Escherich G, Gibson B, Liu H, Loh M, Moorman A, Möricke A, Pieters R, Uyttebroeck A, Baird S, Bartram J, Barzilai-Birenboim S, Batra S, Ben-Harosh M, Bertrand Y, Buitenkamp T, Caldwell K, Drut R, Geerlinks A, Gilad G, Grainger J, Haouy S, Heaney N, Huang M, Ingham D, Krenova Z, Kuhlen M, Lehrnbecher T, Manabe A, Niggli F, Paris C, Revel-Vilk S, Rohrlich P, Sinno M, Szczepanski T, Tamesberger M, Warrier R, Wolfl M, Nirel R, Izraeli S, Borkhardt A, Schmiegelow K
BLOOD. 2023;141(7):743-755.

Long-term sequelae after immunotherapeutic approaches in haematological malignancies-what do we know?
Escherich G, Hough R
LANCET HAEMATOL. 2023;10(6):e395-e396.

Integrating copy number data of 64 iAMP21 BCP-ALL patients narrows the common region of amplification to 1.57 Mb
Hormann F, Hoogkamer A, Boeree A, Sonneveld E, Escherich G, den Boer M, Boer J
FRONT ONCOL. 2023;13:1128560.

Solid pseudopapillary neoplasms of the pancreas in childhood and adolescence-an analysis of the German Registry for Rare Pediatric Tumors (STEP)
Jentzsch C, Fuchs J, Agaimy A, Vokuhl C, Escherich G, Blattmann C, Warmann S, Schmidt A, Schäfer J, Brecht I, Schneider D, Abele M
EUR J PEDIATR. 2023;182(12):5341-5352.

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia
Østergaard A, Enshaei A, Pieters R, Vora A, Horstmann M, Escherich G, Johansson B, Heyman M, Schmiegelow K, Hoogerbrugge P, den Boer M, Kuiper R, Moorman A, Boer J, van Leeuwen F
HEMASPHERE. 2023;7(5):e875.

Emotional and behavioral problems of pediatric cancer survivors and their siblings: Concordance of child self-report and parent proxy-report
Paul V, Inhestern L, Winzig J, Nasse M, Krauth K, Rutkowski S, Escherich G, Bergelt C
PSYCHO-ONCOLOGY. 2023;32(8):1248-1256.

Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials
Raetz E, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, Imai C, De Moerloose B, Schmiegelow K, Burns M, Elitzur S, Pieters R, Attarbaschi A, Yeoh A, Pui C, Stary J, Cario G, Bodmer N, Moorman A, Buldini B, Vora A, Valsecchi M
J CLIN ONCOL. 2023;41(32):5025-5034.

Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia
van der Sluis I, de Lorenzo P, Kotecha R, Attarbaschi A, Escherich G, Nysom K, Stary J, Ferster A, Brethon B, Locatelli F, Schrappe M, Scholte-van Houtem P, Valsecchi M, Pieters R
NEW ENGL J MED. 2023;388(17):1572-1581.

ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia
van Outersterp I, van der Velden V, Hoogeveen P, Vaitkevičienė G, Sonneveld E, van Haaften G, Kuiper R, Zur Stadt U, Escherich G, Boer J, den Boer M
HEMASPHERE. 2023;7(10):e967.

Parent-reported health-related quality of life in pediatric childhood cancer survivors and factors associated with poor health-related quality of life in aftercare
Winzig J, Inhestern L, Paul V, Nasse M, Krauth K, Kandels D, Rutkowski S, Escherich G, Bergelt C
QUAL LIFE RES. 2023;32(10):2965-2974.

Effects of a Pretend Play Intervention on Health-Related Quality of Life in Children With Cancer: A Swedish-German Study
Witt S, Quitmann J, Höglund A, Russ S, Kaman A, Escherich G, Frygner-Holm S
J PEDIAT HEMAT ONC N. 2023;40(3):158-169.

2022

Mucha-Habermann disease: a pediatric case report and proposal of a risk score
Blohm M, Ebenebe C, Rau C, Escherich C, Johannsen J, Escherich G, Driemeyer J, Nagel P, Kobbe R, Lütgehetmann M, Lennartz M, Booken N, Schneider S, Singer D
INT J DERMATOL. 2022;61(4):401-409.

Hypersensitivity to Pegylated E.colia sparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group
Brigitha L, Fiocco M, Pieters R, Albertsen B, Escherich G, Lopez-Lopez E, Mondelaers V, Vora A, Vrooman L, Schmiegelow K, van der Sluis I
EUR J CANCER. 2022;162:65-75.

Looking back: Identifying supportive care and unmet needs of parents of children receiving specialist paediatric palliative care from the bereavement perspective
Bronsema A, Theißen T, Oechsle K, Wikert J, Escherich G, Rutkowski S, Bokemeyer C, Ullrich A
BMC PALLIAT CARE. 2022;21(1):.

Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium
Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M, Cario G, Cazzaniga G, Escherich G, Harrison C, Heyman M, Hunger S, Kiss C, Liu H, Locatelli F, Loh M, Manabe A, Mann G, Pieters R, Pui C, Rives S, Schmiegelow K, Silverman L, Stary J, Vora A, Brown P
BLOOD. 2022;139(12):1785-1793.

Does the Y chromosome play a role for outcome in childhood acute lymphoblastic leukemia?
Conter V, Schrappe M, Escherich G
CANCER-AM CANCER SOC. 2022;128(9):1727-1729.

Akute lymphoblastische Leukämie
Escherich G, Möricke A, Horstmann M, Schrappe M
2022. Kompendium Internistische Onkologie. Schmoll H (Hrsg.). 5. Aufl. Berlin, Heidelberg: Springer, .

Aktualisierte AWMF Leitlinie über die Diagnostik und Therapie der akuten lymphoblastische Leukämie im Kindesalter
Escherich G, Schrappe M
KLIN PADIATR. 2022;234(6):363-367.

Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group
Escherich G, Zur Stadt U, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Spohn M, Zimmermann M, Horstmann M
HAEMATOLOGICA. 2022;107(5):1026-1033.

Children with cancer and their families after active treatment: analyses of biopsychosocial needs and implications for healthcare - a study protocol
Inhestern L, Paul V, Winzig J, Rutkowski S, Escherich G, Bergelt C
BMJ OPEN. 2022;12(4):e055633.

Osteonekrosen – gravierende Therapiefolge bei akuter lymphoblastischer Leukämie
Kuhlen M, Kunstreich M, Gökbuget N, Escherich G
ORTHOPADIE. 2022;51(10):792-799.

Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial
Mezger K, Ebert S, Muhle H, Stadt U, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Zimmermann M, Horstmann M, Escherich G
PEDIATR BLOOD CANCER. 2022;69(12):.

Thirteen-month-old girl with hyporegenerative macrocytic anemia due to Brown-Vialetto-Van Laere syndrome 2
Naami N, Borkhardt A, Yoshimi A, Grinstein L, Escherich G
AM J HEMATOL. 2022;97(11):1495-1496.

Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia
Nielsen R, Wolthers B, Helenius M, Albertsen B, Clemmensen L, Nielsen K, Kanerva J, Niinimäki R, Frandsen T, Attarbaschi A, Barzilai S, Colombini A, Escherich G, Aytan-Aktug D, Liu H, Möricke A, Samarasinghe S, van der Sluis I, Stanulla M, Tulstrup M, Yadav R, Zapotocka E, Schmiegelow K, Gupta R
J PEDIAT HEMATOL ONC. 2022;44(3):e628-e636.

Fear of progression in parents of childhood cancer survivors: prevalence and associated factors
Peikert M, Inhestern L, Krauth K, Escherich G, Rutkowski S, Kandels D, Schiekiera L, Bergelt C
J CANCER SURVIV. 2022;16(4):823-833.

Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia
Ramos-Muntada M, Trincado J, Blanco J, Bueno C, Rodríguez-Cortez V, Bataller A, López-Millán B, Schwab C, Ortega M, Velasco P, Blanco M, Nomdedeu J, Ramírez-Orellana M, Minguela A, Fuster J, Cuatrecasas E, Camós M, Ballerini P, Escherich G, Boer J, DenBoer M, Hernández-Rivas J, Calasanz M, Cazzaniga G, Harrison C, Menéndez P, Molina O
MOL ONCOL. 2022;16(16):2899-2919.

Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution
Richter-Pechańska P, Kunz J, Rausch T, Erarslan-Uysal B, Bornhauser B, Frismantas V, Assenov Y, Zimmermann M, Happich M, von Knebel-Doeberitz C, von Neuhoff N, Köhler R, Stanulla M, Schrappe M, Cario G, Escherich G, Kirschner-Schwabe R, Eckert C, Avigad S, Pfister S, Muckenthaler M, Bourquin J, Korbel J, Kulozik A
LEUKEMIA. 2022;36(7):1759-1768.

Multimodal Treatment of Nasopharyngeal Carcinoma in Children, Adolescents and Young Adults-Extended Follow-Up of the NPC-2003-GPOH Study Cohort and Patients of the Interim Cohort
Römer T, Franzen S, Kravets H, Farrag A, Makowska A, Christiansen H, Eble M, Timmermann B, Staatz G, Mottaghy F, Bührlen M, Hagenah U, Puzik A, Driever P, Greiner J, Jorch N, Tippelt S, Schneider D, Kropshofer G, Overbeck T, Christiansen H, Brozou T, Escherich G, Becker M, Friesenbichler W, Feuchtinger T, Puppe W, Heussen N, Hilgers R, Kontny U
CANCERS. 2022;14(5):.

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol
Stutterheim J, de Lorenzo P, van der Sluis I, Alten J, Ancliffe P, Attarbaschi A, Aversa L, Boer J, Biondi A, Brethon B, Diaz P, Cazzaniga G, Escherich G, Ferster A, Kotecha R, Lausen B, Leung A, Locatelli F, Silverman L, Stary J, Szczepanski T, van der Velden V, Vora A, Zuna J, Schrappe M, Valsecchi M, Pieters R
EUR J CANCER. 2022;160:72-79.

Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol
Toksvang L, Als-Nielsen B, Bacon C, Bertasiute R, Duarte X, Escherich G, Helgadottir E, Johannsdottir I, Jónsson Ó, Kozlowski P, Langenskjöld C, Lepik K, Niinimäki R, Overgaard U, Punab M, Räty R, Segers H, van der Sluis I, Smith O, Strullu M, Vaitkevičienė G, Wik H, Heyman M, Schmiegelow K
BMC CANCER. 2022;22(1):.

2021

Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia
Andrés-Jensen L, Attarbaschi A, Bardi E, Barzilai-Birenboim S, Bhojwani D, Hagleitner M, Halsey C, Harila-Saari A, van Litsenburg R, Hudson M, Jeha S, Kato M, Kremer L, Mlynarski W, Möricke A, Pieters R, Piette C, Raetz E, Ronceray L, Toro C, Grazia Valsecchi M, Vrooman L, Weinreb S, Winick N, Schmiegelow K
LANCET HAEMATOL. 2021;8(7):e513-e523.

Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study
Boer J, Valsecchi M, Hormann F, Antić Ž, Zaliova M, Schwab C, Cazzaniga G, Arfeuille C, Cavé H, Attarbaschi A, Strehl S, Escherich G, Imamura T, Ohki K, Grüber T, Sutton R, Pastorczak A, Lammens T, Lambert F, Li C, Carrillo de Santa Pau E, Hoffmann S, Möricke A, Harrison C, Den Boer M, De Lorenzo P, Stam R, Bergmann A, Pieters R
LEUKEMIA. 2021;35(10):2978-2982.

Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era. a multicentre, retrospective, cohort study
den Boer M, Cario G, Moorman A, Boer J, de Groot-Kruseman H, Fiocco M, Escherich G, Imamura T, Yeoh A, Sutton R, Dalla-Pozza L, Kiyokawa N, Schrappe M, Roberts K, Mullighan C, Hunger S, Vora A, Attarbaschi A, Zaliova M, Elitzur S, Cazzaniga G, Biondi A, Loh M, Pieters R
LANCET HAEMATOL. 2021;8(1):e55-e66.

A "Goldilocks" approach to CNS leukemia is needed
Halsey C, Escherich G
BLOOD. 2021;138(4):288-289.

Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study
Michels N, Boer J, Enshaei A, Sutton R, Heyman M, Ebert S, Fiocco M, de Groot-Kruseman H, van der Velden V, Barbany G, Escherich G, Vora A, Trahair T, Dalla-Pozza L, Pieters R, Zur Stadt U, Schmiegelow K, Moorman A, Zwaan C, den Boer M
LANCET HAEMATOL. 2021;8(10):e700-e710.

Effects of a structured counselling-based intervention to improve physical activity behaviour of adolescents and young adult cancer survivors - the randomized phase II Motivate AYA - MAYA trial
Salchow J, Koch B, Mann J, von Grundherr J, Elmers S, Dwinger S, Escherich G, Vettorazzi E, Reer R, Sinn M, Baumann F, Bokemeyer C, Stein A, Jensen W
CLIN REHABIL. 2021;35(8):1164-1174.

SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome
Schwab C, Roberts K, Boer J, Gohring G, Steinemann D, Vora A, Macartney C, Hough R, Thorn Z, Dillon R, Escherich G, Cazzaniga G, Schlegelberger B, Loh M, Den Boer M, Moorman A, Harrison C
BLOOD. 2021;137(13):1835-1838.

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
Stutterheim J, van der Sluis I, de Lorenzo P, Alten J, Ancliffe P, Attarbaschi A, Brethon B, Biondi A, Campbell M, Cazzaniga G, Escherich G, Ferster A, Kotecha R, Lausen B, Li C, Lo Nigro L, Locatelli F, Marschalek R, Meyer C, Schrappe M, Stary J, Vora A, Zuna J, van der Velden V, Szczepanski T, Valsecchi M, Pieters R
J CLIN ONCOL. 2021;39(6):652-662.

Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome
Winter G, Kirschner-Schwabe R, Groeneveld-Krentz S, Escherich G, Möricke A, von Stackelberg A, Stanulla M, Bailey S, Richter L, Steinemann D, Ripperger T, Escudero A, Farah R, Lohi O, Wadt K, Jongmans M, van Engelen N, Eckert C, Kratz C
LEUKEMIA. 2021;35(5):1475-1479.

2020

Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients
Blaeschke F, Willier S, Stenger D, Lepenies M, Horstmann M, Escherich G, Zimmermann M, Rojas Ringeling F, Canzar S, Kaeuferle T, Rohlfs M, Binder V, Klein C, Feuchtinger T
LEUKEMIA. 2020;34(10):2607-2620.

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia
Enshaei A, O'Connor D, Bartram J, Hancock J, Harrison C, Hough R, Samarasinghe S, den Boer M, Boer J, de Groot-Kruseman H, Marquart H, Noren-Nystrom U, Schmiegelow K, Schwab C, Horstmann M, Escherich G, Heyman M, Pieters R, Vora A, Moppett J, Moorman A
BLOOD. 2020;135(17):1438-1446.

Chromatin accessibility landscape of pediatric T-lymphoblastic leukemia and human T-cell precursors
Erarslan-Uysal B, Kunz J, Rausch T, Richter-Pechańska P, van Belzen I, Frismantas V, Bornhauser B, Ordoñez-Rueada D, Paulsen M, Benes V, Stanulla M, Schrappe M, Cario G, Escherich G, Bakharevich K, Kirschner-Schwabe R, Eckert C, Loukanov T, Gorenflo M, Waszak S, Bourquin J, Muckenthaler M, Korbel J, Kulozik A
EMBO MOL MED. 2020;12(9):e12104.

Juvenile Blastic Plasmacytoid Dendritic Cell Neoplasm
Hayani K, Escherich G, Koch K, French L, Wolff H
ACTA DERM-VENEREOL. 2020;100(15):adv00245.

Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment
Hrusak O, Kalina T, Wolf J, Balduzzi A, Provenzi M, Rizzari C, Rives S, Del Pozo Carlavilla M, Alonso M, Domínguez-Pinilla N, Bourquin J, Schmiegelow K, Attarbaschi A, Grillner P, Mellgren K, van der Werff Ten Bosch J, Pieters R, Brozou T, Borkhardt A, Escherich G, Lauten M, Stanulla M, Smith O, Yeoh A, Elitzur S, Vora A, Li C, Ariffin H, Kolenova A, Dallapozza L, Farah R, Lazic J, Manabe A, Styczynski J, Kovacs G, Ottoffy G, Felice M, Buldini B, Conter V, Stary J, Schrappe M
EUR J CANCER. 2020;132:11-16.

Parents' perception of their children's process of reintegration after childhood cancer treatment
Inhestern L, Peikert M, Krauth K, Escherich G, Rutkowski S, Kandels D, Bergelt C
PLOS ONE. 2020;15(10):e0239967.

Fear of progression in parents of childhood cancer survivors: A Dyadic data analysis
Peikert M, Inhestern L, Krauth K, Escherich G, Rutkowski S, Kandels D, Bergelt C
PSYCHO-ONCOLOGY. 2020;29(10):1678-1685.

Returning to daily life: a qualitative interview study on parents of childhood cancer survivors in Germany
Peikert M, Inhestern L, Krauth K, Escherich G, Rutkowski S, Kandels D, Bergelt C
BMJ OPEN. 2020;10(3):e033730.

Social inequalities in the participation and activity of children and adolescents with leukemia, brain tumors, and sarcomas (SUPATEEN): a protocol for a multicenter longitudinal prospective observational study
Roick J, Berner R, Bernig T, Erdlenbruch B, Escherich G, Faber J, Klein C, Bochennek K, Kratz C, Kühr J, Längler A, Lode H, Metzler M, Müller H, Reinhardt D, Sauerbrey A, Schepper F, Scheurlen W, Schneider D, Schwabe G, Richter M
BMC PEDIATR. 2020;20(1):48.

Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review
Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, Straub L, Vettorazzi E, Escherich G, Rutkowski S, Dwinger S, Bergelt C, Sokalska-Duhme M, Bielack S, Calaminus G, Baust K, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Gebauer J, Langer T, Metzler M, Schuster S, Niemeyer C, Puzik A, Reinhardt D, Dirksen U, Sander A, Köhler M, Habermann J, Bokemeyer C, Stein A
BMC CANCER. 2020;20(1):16.

Can we optimise doxorubicin treatment regimens for children with cancer?: Pharmacokinetic simulations and a Delphi consensus procedure
Siebel C, Würthwein G, Lanvers-Kaminsky C, André N, Berthold F, Castelli I, Chastagner P, Doz F, English M, Escherich G, Frühwald M, Graf N, Groll A, Ruggiero A, Hempel G, Boos J
BMC PHARMACOL TOXICO. 2020;21(1):37.

2019

Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL
Babor F, Peters C, Manser A, Glogova E, Sauer M, Pötschger U, Ahlmann M, Cario G, Feuchtinger T, Gruhn B, Güngör T, Kremens B, Lang P, Mezger M, Müller I, Mytilineos J, Oevermann L, Pichler H, Scherenschlich N, Schuster F, Siepermann M, Stachel D, Strahm B, Wössmann W, Escherich G, Zimmermann M, Schrappe M, Borkhardt A, Eckert C, Bader P, Uhrberg M, Meisel R
BONE MARROW TRANSPL. 2019;54(11):1847-1858.

Long-term follow-up of Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor
Biondi A, Cario G, De Lorenzo P, Castor A, Conter V, Leoni V, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Attarbaschi A, Li C, Vora A, Bradtke J, Saha V, Valsecchi M, Schrappe M
HAEMATOLOGICA. 2019;104(1):e13-e16.

Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics
Eckert C, Groeneveld-Krentz S, Kirschner-Schwabe R, Hagedorn N, Chen-Santel C, Bader P, Borkhardt A, Cario G, Escherich G, Panzer-Grümayer R, Astrahantseff K, Eggert A, Sramkova L, Attarbaschi A, Bourquin J, Peters C, Henze G, von Stackelberg A
J CLIN ONCOL. 2019;37(36):3493-3506.

Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets
Hoell J, Ginzel S, Kuhlen M, Kloetgen A, Gombert M, Fischer U, Hein D, Demir S, Stanulla M, Schrappe M, Zur Stadt U, Bader P, Babor F, Schuster F, Strahm B, Alten J, Moericke A, Escherich G, von Stackelberg A, Thiele R, McHardy A, Peters C, Bornhauser B, Bourquin J, Krause S, Enczmann J, Meyer L, Eckert C, Borkhardt A, Meisel R
BLOOD ADV. 2019;3(20):3143-3156.

NUTM1 is a recurrent fusion gene partner in B cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2
Hormann F, Hoogkamer A, Beverloo H, Boeree A, Dingjan I, Wattel M, Stam R, Escherich G, Pieters R, den Boer M, Boer J
HAEMATOLOGICA. 2019;104(10):e455-e459.

Osteonecrosis in children with acute lymphoblastic leukemia at initial diagnosis and prior to any chemotherapy
Krull K, Kunstreich M, Bronsema A, Bleckmann K, Classen C, Erdlenbruch B, Jorch N, Kolb R, Leipold A, Moser O, Prokop A, Scheurlen W, Steinbach D, Klasen-Sansone J, Klee D, Escherich G, Moericke A, Schrappe M, Borkhardt A, Kuhlen M
LEUKEMIA LYMPHOMA. 2019;60(1):78-84.

Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions
Meyer C, Lopes B, Caye-Eude A, Cavé H, Arfeuille C, Cuccuini W, Sutton R, Venn N, Oh S, Tsaur G, Escherich G, Feuchtinger T, Kosasih H, Khaw S, Ekert P, Pombo-de-Oliveira M, Bidet A, Djahanschiri B, Ebersberger I, Zaliova M, Zuna J, Zermanova Z, Juvonen V, Grümayer R, Fazio G, Cazzaniga G, Larghero P, Emerenciano M, Marschalek R
LEUKEMIA. 2019;33(9):2306-2340.

Gemtuzumab Ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group
Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin J, Dworzak M, Sramkova L, Rossig C, Creutzig U, Reinhardt D, Rasche M
HAEMATOLOGICA. 2019;104(1):120-127.

Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
Pieters R, De Lorenzo P, Ancliffe P, Aversa L, Brethon B, Biondi A, Campbell M, Escherich G, Ferster A, Gardner R, Kotecha R, Lausen B, Li C, Locatelli F, Attarbaschi A, Peters C, Rubnitz J, Silverman L, Stary J, Szczepanski T, Vora A, Schrappe M, Valsecchi M
J CLIN ONCOL. 2019;37(25):2246-2256.

Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09
Schramm F, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Feuchtinger T, Schmid I, Beron G, Horstmann M, Escherich G
LEUKEMIA LYMPHOMA. 2019;60(1):60-68.

Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity
Schramm F, Zur Stadt U, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Schmid I, Feuchtinger T, Beron G, den Boer M, Pieters R, Horstmann M, Janka-Schaub G, Escherich G
BLOOD ADV. 2019;3(22):3688-3699.

Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia
Steeghs E, Boer J, Hoogkamer A, Boeree A, de Haas V, de Groot-Kruseman H, Horstmann M, Escherich G, Pieters R, den Boer M
SCI REP-UK. 2019;9(1):4634.

Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report
Wolthers B, Frandsen T, Patel C, Abaji R, Attarbaschi A, Barzilai S, Colombini A, Escherich G, Grosjean M, Krajinovic M, Larsen E, Liang D, Möricke A, Rasmussen K, Samarasinghe S, Silverman L, van der Sluis I, Stanulla M, Tulstrup M, Yadav R, Yang W, Zapotocka E, Gupta R, Schmiegelow K
HAEMATOLOGICA. 2019;104(3):556-563.

Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL
Zur Stadt U, Alawi M, Adao M, Indenbirken D, Escherich G, Horstmann M
BLOOD CANCER J. 2019;9(12):96.

2018

Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial
Biondi A, Gandemer V, De Lorenzo P, Cario G, Campbell M, Castor A, Pieters R, Baruchel A, Vora A, Leoni V, Stary J, Escherich G, Li C, Cazzaniga G, Cavé H, Bradtke J, Conter V, Saha V, Schrappe M, Grazia Valsecchi M
LANCET HAEMATOL. 2018;5(12):e641-e652.

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen H, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari G, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt U, Aricò M, Conter V, Schrappe M, Valsecchi M, Biondi A
HAEMATOLOGICA. 2018;103(1):107-115.

Comment on: "Successful use of nitrous oxide during lumbar punctures: A call for nitrous oxide in pediatric oncology clinics"
Forster V, Escherich G, Halsey C
PEDIATR BLOOD CANCER. 2018;65(5):e26930.

RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia
Jerchel I, Hoogkamer A, Ariës I, Steeghs E, Boer J, Besselink N, Boeree A, van de Ven C, de Groot-Kruseman H, de Haas V, Horstmann M, Escherich G, Zwaan C, Cuppen E, Koudijs M, Pieters R, den Boer M
LEUKEMIA. 2018;32(4):931-940.

Inflammatory myofibroblastic tumors-A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe
Kube S, Vokuhl C, Dantonello T, Scheer M, Hallmen E, Feuchtgruber S, Escherich G, Niggli F, Kuehnle I, von Kalle T, Bielack S, Klingebiel T, Koscielniak E
PEDIATR BLOOD CANCER. 2018;65(6):e27012.

Langzeitbeobachtung ehemaliger krebskranker Kinder und Jugendlicher
Langer T, Grabow D, Kaatsch P, Creutzig U, Eggert A, Escherich G, Calaminus G
KLIN PADIATR. 2018;230(6):291-298.

Hypereosinophilia as Presenting Symptom of a Pre-B-ALL
Maier S, Zoghbi A, Escherich G, Winkler B
KLIN PADIATR. 2018;230(3):160-161.

PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia
Richter-Pechańska P, Kunz J, Bornhauser B, von Knebel Doeberitz C, Rausch T, Erarslan-Uysal B, Assenov Y, Frismantas V, Marovca B, Waszak S, Zimmermann M, Seemann J, Happich M, Stanulla M, Schrappe M, Cario G, Escherich G, Bakharevich K, Kirschner-Schwabe R, Eckert C, Muckenthaler M, Korbel J, Bourquin J, Kulozik A
EMBO MOL MED. 2018;10(12):e9443.

High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia
Steeghs E, Bakker M, Hoogkamer A, Boer J, Hartman Q, Stalpers F, Escherich G, de Haas V, de Groot-Kruseman H, Pieters R, den Boer M
SCI REP-UK. 2018;8(1):693.

Exploring the potential of a pretend play intervention in young patients with leukemia
Witt S, Escherich G, Rutkowski S, Kappelhoff G, Frygner-Holm S, Russ S, Bullinger M, Quitmann J
J PEDIATR NURS. 2018;44:E98-E106.

2017

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia
Boer J, Steeghs E, Marchante J, Boeree A, Beaudoin J, Beverloo H, Kuiper R, Escherich G, van der Velden V, van der Schoot C, de Groot-Kruseman H, Pieters R, den Boer M
ONCOTARGET. 2017;8(3):4618-4628.

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol
Driessen E, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li C, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R
LEUKEMIA. 2017;31(12):2854.

Building a National Framework for Adolescent and Young Adult Hematology and Oncology and Transition from Pediatric to Adult Care: Report of the Inaugural Meeting of the "AjET" Working Group of the German Society for Pediatric Oncology and Hematology
Escherich G, Bielack S, Maier S, Braungart R, Brümmendorf T, Freund M, Grosse R, Hoferer A, Kampschulte R, Koch B, Lauten M, Milani V, Ross H, Schilling F, Wöhrle D, Cario H, Dirksen U
J ADOLESC YOUNG ADUL. 2017;6(2):194-199.

Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN
Kilday J, Caldarelli M, Massimi L, Chen R, Lee Y, Liang M, Parkes J, Naiker T, van Veelen M, Michiels E, Mallucci C, Pettorini B, Meijer L, Dorfer C, Czech T, Diezi M, Schouten-van Meeteren A, Holm S, Gustavsson B, Benesch M, Müller H, Hoffmann A, Rutkowski S, Flitsch J, Escherich G, Grotzer M, Spoudeas H, Azquikina K, Capra M, Jiménez-Guerra R, MacDonald P, Johnston D, Dvir R, Constantini S, Kuo M, Yang S, Bartels U
NEURO-ONCOLOGY. 2017;19(10):1398-1407.

Osteonecrosis develops independently from radiological leukemic infiltration of bone in adolescents with acute lymphoblastic leukemia - first findings of the OPAL trial
Krull K, Kunstreich M, Klasen-Sansone J, Kloetgen A, Gruener F, Escherich G, Bleckmann K, Moericke A, Schrappe M, Jorch N, Steinbach D, Classen C, Guggemos A, Kolb R, Klee D, Borkhardt A, Kuhlen M
LEUKEMIA LYMPHOMA. 2017;58(10):2363-2369.

Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy
Kuhlen M, Bleckmann K, Möricke A, Schrappe M, Vieth S, Escherich G, Bronsema A, Vonalt A, Queudeville M, Zwaan C, Ebinger M, Debatin K, Klingebiel T, Koscielniak E, Rossig C, Burkhardt B, Kolb R, Eckert C, Borkhardt A, von Stackelberg A, Chen-Santel C
BRIT J HAEMATOL. 2017;179(2):272-283.

Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma
Landmann E, Burkhardt B, Zimmermann M, Meyer U, Woessmann W, Klapper W, Wrobel G, Rosolen A, Pillon M, Escherich G, Attarbaschi A, Beishuizen A, Mellgren K, Wynn R, Ratei R, Plesa A, Schrappe M, Reiter A, Bergeron C, Patte C, Bertrand Y
HAEMATOLOGICA. 2017;102(12):2086-2096.

Das CARE-for-CAYA-Programm. Präventionskonzept für junge Menschen nach Krebserkrankung
Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2017;32(06):479-484.

Versorgung von Patienten nach Krebserkrankung im Kindes-, Jugend- oder jungen Erwachsenenalter
Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
J Onkol - Z Onkol Fortb. 2017;2017(10):862-866.

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004
Rasche M, von Neuhoff C, Dworzak M, Bourquin J, Bradtke J, Göhring G, Escherich G, Fleischhack G, Graf N, Gruhn B, Haas O, Klingebiel T, Kremens B, Lehrnbecher T, von Stackelberg A, Tchinda J, Zemanova Z, Thiede C, von Neuhoff N, Zimmermann M, Creutzig U, Reinhardt D
LEUKEMIA. 2017;31(12):2807-2814.

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients
Scheijen B, Boer J, Marke R, Tijchon E, van Ingen Schenau D, Waanders E, van Emst L, van der Meer L, Pieters R, Escherich G, Horstmann M, Sonneveld E, Venn N, Sutton R, Dalla-Pozza L, Kuiper R, Hoogerbrugge P, den Boer M, van Leeuwen F
HAEMATOLOGICA. 2017;102(3):541-551.

Clinical and Molecular Heterogeneity of RTEL1 Deficiency
Speckmann C, Sahoo S, Rizzi M, Hirabayashi S, Karow A, Serwas N, Hoemberg M, Damatova N, Schindler D, Vannier J, Boulton S, Pannicke U, Göhring G, Thomay K, Verdu-Amoros J, Hauch H, Woessmann W, Escherich G, Laack E, Rindle L, Seidl M, Rensing-Ehl A, Lausch E, Jandrasits C, Strahm B, Schwarz K, Ehl S, Niemeyer C, Boztug K, Wlodarski M
FRONT IMMUNOL. 2017;8:449.

Corrigendum: Clinical and Molecular Heterogeneity of RTEL1 Deficiency
Speckmann C, Sahoo S, Rizzi M, Hirabayashi S, Karow A, Serwas N, Hoemberg M, Damatova N, Schindler D, Vannier J, Boulton S, Pannicke U, Göhring G, Thomay K, Verdu-Amoros J, Hauch H, Woessmann W, Escherich G, Laack E, Rindle L, Seidl M, Rensing-Ehl A, Lausch E, Jandrasits C, Strahm B, Schwarz K, Ehl S, Niemeyer C, Boztug K, Wlodarski M
FRONT IMMUNOL. 2017;8:1250.

Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study
Wolthers B, Frandsen T, Baruchel A, Attarbaschi A, Barzilai S, Colombini A, Escherich G, Grell K, Inaba H, Kovacs G, Liang D, Mateos M, Mondelaers V, Möricke A, Ociepa T, Samarasinghe S, Silverman L, van der Sluis I, Stanulla M, Vrooman L, Yano M, Zapotocka E, Schmiegelow K
LANCET ONCOL. 2017;18(9):1238-1248.

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement
Zoghbi A, Zur Stadt U, Winkler B, Müller I, Escherich G
PEDIATR BLOOD CANCER. 2017;64(11):11.

2016

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol
Driessen E, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li C, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R
LEUKEMIA. 2016;30(5):1184-1187.

Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation
Kloos R, Pieters R, Escherich G, van der Sluis I
PEDIATR BLOOD CANCER. 2016;63(11):1928-34.

Improved nutrition in adolescents and young adults after childhood cancer - INAYA study
Quidde J, von Grundherr J, Koch B, Bokemeyer C, Escherich G, Valentini L, Buchholz D, Schilling G, Stein A
BMC CANCER. 2016;16(1):872.

Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia Treatment: a Delphi consensus
Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen T, Halsey C, Hough R, Jeha S, Kato M, Liang D, Mikkelsen T, Möricke A, Niinimäki R, Piette C, Putti M, Raetz E, Silverman L, Skinner R, Tuckuviene R, van der Sluis I, Zapotocka E
LANCET ONCOL. 2016;17(6):e231-9.

Rapid Capture Next-Generation Sequencing in Clinical Diagnostics of Kinase Pathway Aberrations in B-Cell Precursor ALL
Stadt U, Escherich G, Indenbirken D, Alawi M, Adao M, Horstmann M
PEDIATR BLOOD CANCER. 2016;63(7):1283-6.

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
van der Sluis I, Vrooman L, Pieters R, Baruchel A, Escherich G, Goulden N, Mondelaers V, de Toledo J, Rizzari C, Silverman L, Whitlock J
HAEMATOLOGICA. 2016;101(3):279-85.

Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy
Vora A, Andreano A, Pui C, Hunger S, Schrappe M, Moericke A, Biondi A, Escherich G, Silverman L, Goulden N, Taskinen M, Pieters R, Horibe K, Devidas M, Locatelli F, Valsecchi M
J CLIN ONCOL. 2016;34(9):919-26.

The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia
Wojtuszkiewicz A, Assaraf Y, Hoekstra M, Sciarrillo R, Jansen G, Peters G, Pieters R, Sonneveld E, Escherich G, Kaspers G, Cloos J
HAEMATOLOGICA. 2016;101(7):e291-4.

2015

BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures
Boer J, Marchante J, Evans W, Horstmann M, Escherich G, Pieters R, Den Boer M
HAEMATOLOGICA. 2015;100(9):e354-7.

Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: Prognostic relevance of early and late assessment
Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, Bourquin J, Klingebiel T, Borkhardt A, Cario G, Alten J, Escherich G, Astrahantseff K, Seeger K, Henze G, von Stackelberg A
LEUKEMIA. 2015;29(8):1648-1655.

Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia
Löbel U, Trah J, Escherich G
PEDIATR BLOOD CANCER. 2015;62(3):539-41.

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Pui C, Yang J, Hunger S, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman L, Schmiegelow K, Escherich G, Horibe K, Benoit Y, Izraeli S, Yeoh A, Liang D, Downing J, Evans W, Relling M, Mullighan C
J CLIN ONCOL. 2015;33(27):2938-48.

Psychische Belastungen von Kindern und Jugendlichen nach einer Leukämie oder Lymphomerkrankung
Sautier L, Sarkar S, Petersen M, Mehnert A, Escherich G
PRAX KINDERPSYCHOL K. 2015;64(4):273-289.

Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
Wojtuszkiewicz A, Peters G, van Woerden N, Dubbelman B, Escherich G, Schmiegelow K, Sonneveld E, Pieters R, van de Ven P, Jansen G, Assaraf Y, Kaspers G, Cloos J
HEMATOL ONCOL. 2015;8:61.

2014

EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion
Ariës I, Jerchel I, van den Dungen R, van den Berk L, Boer J, Horstmann M, Escherich G, Pieters R, den Boer M
LEUKEMIA. 2014;28(9):1828-1837.

Acute lymphoblastic leukemia in children with Down Syndrome: a retrospective analysis from the Ponte di Legno study group
Buitenkamp T, Izraeli S, Zimmermann M, Forestier E, Heerema N, van den Heuvel-Eibrink M, Pieters R, Korbijn C, Silverman L, Schmiegelow K, Liang D, Horibe K, Arico M, Biondi A, Basso G, Rabin K, Schrappe M, Cario G, Mann G, Morak M, Panzer-Grümayer R, Mondelaers V, Lammens T, Cavé H, Stark B, Ganmore I, Moorman A, Vora A, Hunger S, Pui C, Mullighan C, Manabe A, Escherich G, Kowalczyk J, Whitlock J, Zwaan C
BLOOD. 2014;123(1):70-77.

Significantly increased CD70 up regulation on TEL-AML positive B cell precursor acute lymphoblastic leukemia cells following CD40 stimulation
Troeger A, Glouchkova L, Ackermann B, Escherich G, Hanenberg H, Janka G, Roettgers S, Göbel U, Dilloo D
KLIN PADIATR. 2014;226(6-7):332-337.

Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia
van der Veer A, van der Velden V, Willemse M, Hoogeveen P, Petricoin E, Beverloo H, Escherich G, Horstmann M, Pieters R, den Boer M
BLOOD CANCER J. 2014;4:e181.

2013

PGK1 as predictor of CXCR4 expression, bone marrow metastases and survival in neuroblastoma
Ameis H, Drenckhan A, Loga K, Escherich G, Wenke K, Izbicki J, Reinshagen K, Gros S
PLOS ONE. 2013;8(12):e83701.

Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence
Bonn B, Rohde M, Zimmermann M, Krieger D, Oschlies I, Niggli F, Wrobel G, Attarbaschi A, Escherich G, Klapper W, Reiter A, Burkhardt B
BLOOD. 2013;121(16):3153-60.

Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group
Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grümayer R, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Schrauder A, Escherich G, Sramkova L, Niggli F, Hitzler J, von Stackelberg A
J CLIN ONCOL. 2013;31(21):2736-42.

Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C, von Stackelberg A, Seeger K, Groeneveld T, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G
EUR J CANCER. 2013;49(6):1346-1355.

Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
Escherich G, Zimmermann M, Janka-Schaub G
PEDIATR BLOOD CANCER. 2013;60(2):254-257.

Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial
Escherich G, Zur Stadt U, Zimmermann M, Horstmann M
BRIT J HAEMATOL. 2013;163(2):240-7.

Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia
Hartz B, Löbel U, Hagel C, Escherich G
AM J HEMATOL. 2013;88(12):1096-7.

Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts
Lange T, Stehling C, Fröhlich B, Klingenhöfer M, Kunkel P, Schneppenheim R, Escherich G, Gosheger G, Hardes J, Jürgens H, Schulte T
EUR SPINE J. 2013;22(6):1417-22.

Refinement of IKZF1 recombination hotspots in pediatric BCP-ALL patients.
Meyer C, Zur Stadt U, Escherich G, Hofmann J, Binato R, Barbosa T, Emerenciano M, Pombo-de-Oliveira M, Horstmann M, Marschalek R
AM J BLOOD RES. 2013;3(2):165-173.

Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome
Meyr F, Escherich G, Mann G, Klingebiel T, Kulozik A, Rossig C, Schrappe M, Henze G, von Stackelberg A, Hitzler J
BRIT J HAEMATOL. 2013;162(1):98-106.

Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia
Richards S, Pui C, Gayon P
PEDIATR BLOOD CANCER. 2013;60(2):185-95.

Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia
Schmiegelow K, Levinsen M, Attarbaschi A, Baruchel A, Devidas M, Escherich G, Gibson B, Heydrich C, Horibe K, Ishida Y, Liang D, Locatelli F, Michel G, Pieters R, Piette C, Pui C, Raimondi S, Silverman L, Stanulla M, Stark B, Winick N, Valsecchi M
J CLIN ONCOL. 2013;31(19):2469-76.

Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia
van der Sluis I, Möricke A, Escherich G, von Stackelberg A, Holter W, Klingebiel T, Flotho C, Legien S, Tissing W, Bierings M, Guimbal-Schmolck C, Pichlmeier U, Kühnel H, Pieters R
HAEMATOLOGICA. 2013;98(11):1697-701.

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL
van der Veer A, Waanders E, Pieters R, Willemse M, Van Reijmersdal S, Russell L, Harrison C, Evans W, van der Velden V, Hoogerbrugge P, Van Leeuwen F, Escherich G, Horstmann M, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman H, Sonneveld E, Kuiper R, Den Boer M
BLOOD. 2013;122(15):2622-9.

2012

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Biondi A, Schrappe M, Paola D, Castor A, Lucchini G, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Li C, Vora A, Aricò M, Röttgers S, Saha V, Valsecchi M
LANCET ONCOL. 2012;13(9):936-945.

Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Pauli S, Steinemann D, Dittmann K, Wienands J, Shoukier M, Möschner M, Burfeind P, Manukjan G, Göhring G, Escherich G
AM J MED GENET A. 2012;158A(3):652-658.

Outcomes after induction failure in childhood acute lymphoblastic leukemia.
Schrappe M, Hunger S, Pui C, Saha V, Gaynon P, Baruchel A, Conter V, Otten J, Ohara A, Versluys A, Escherich G, Heyman M, Silverman L, Horibe K, Mann G, Camitta B, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M
NEW ENGL J MED. 2012;366(15):1371-1381.

2011

Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey.
Bienemann K, Burkhardt B, Modlich S, Meyer U, Möricke A, Bienemann K, Mauz-Körholz C, Escherich G, Zimmermann M, Körholz D, Janka-Schaub G, Schrappe M, Reiter A, Borkhardt A
BRIT J HAEMATOL. 2011;155(4):468-476.

Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.
Escherich G, Richards S, Stork L, Vora A
LEUKEMIA. 2011;25(6):953-959.

The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
Escherich G, Troeger A, Gobel U, Graubner U, Pekrun A, Jorch N, Kaspers G, Zimmermann M, Zur Stadt U, Kazemir K, Pieters R, Horstmann M, Denboer M, Janka-Schaub G
HAEMATOLOGICA. 2011;96(6):854-862.

Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group.
von Stackelberg A, Völzke E, Kühl J, Seeger K, Schrauder A, Escherich G, Henze G, Tallen G, Group A
EUR J CANCER. 2011;47(1):90-97.

2010

Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.
Aricò M, Schrappe M, Hunger S, Carroll W, Conter V, Galimberti S, Manabe A, Saha V, Baruchel A, Vettenranta K, Horibe K, Benoit Y, Pieters R, Escherich G, Silverman L, Pui C, Valsecchi M
J CLIN ONCOL. 2010;28(31):4755-4761.

Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.
Escherich G, Horstmann M, Zimmermann M, Janka-Schaub G
LEUKEMIA. 2010;24(2):298-308.

Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M, Klingebiel T, Fengler R, Henze G, von Stackelberg A
J CLIN ONCOL. 2010;28(14):2339-2347.

2009

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.
Den B, Monique L, Slegtenhorst v, Marjon [, Menezes D, Renée X, Cheok [, Meyling H, Buijs-Gladdines [, Jessica G, Peters [, Susan T, Zutven V, Laura J, Beverloo [, Berna H, Spek V, Peter J, Escherich G, Gaby [, Horstmann M, Martin A, Janka-Schaub G, Gritta E, Kamps [, Willem A, Evans [, William E, Pieters [, Rob [
LANCET ONCOL. 2009;10(2):125-134.

2008

Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A
EUR J CANCER. 2008;44(2):257-268.

Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia.
Graubner U, Porzig S, Jorch N, Kolb R, Wessalowski R, Escherich G, Janka-Schaub G
PEDIATR BLOOD CANCER. 2008;50(2):259-263.

High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95.
Troeger A, Glouchkova L, Ackermann B, Escherich G, Meisel R, Hanenberg H, Boer d, Monique L, Janka-Schaub G, Janka-Schaub G, Goebel U, Laws H, Dilloo D
BLOOD. 2008;112(4):1028-1034.

Reduced expression and defective modulation of TNF receptor/ligand family molecules on proB-ALL blasts.
Troeger A, Glouchkova L, Escherich G, Siepermann M, Hanenberg H, Janka-Schaub G, Göbel U, Ackermann B, Dilloo D
KLIN PADIATR. 2008;220(6):353-357.

2007

Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
Escherich G, Göbel U, Jorch N, Spaar H, Janka-Schaub G
KLIN PADIATR. 2007;219(3):134-138.

High nerve growth factor receptor (p75NTR) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia.
Troeger A, Gudowius S, Escherich G, Boer d, Monique L, Glouchkova L, Ackermann B, Meisel R, Laws H, Groeger M, Wessalowski R, Willers R, Harbott J, Pieters R, Janka-Schaub G, Janka-Schaub G, Hanenberg H, Dilloo D
BRIT J HAEMATOL. 2007;139(3):450-457.

Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia.
Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, Moritz T, Laws H, Hanenberg H, Goebel U, Janka-Schaub G, Mahotka C, Dilloo D
HAEMATOLOGICA. 2007;92(8):1043-1050.

Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia.
Tröger A, Siepermann M, Mahotka C, Wethkamp N, Bülle H, Laws H, Escherich G, Janka-Schaub G, Göbel U, Dilloo D
KLIN PADIATR. 2007;219(3):127-133.

2005

Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Horstmann M, Hassenpflug W, Udo Z, Escherich G, Janka-Schaub G, Kabisch H
HAEMATOLOGICA. 2005;90(12):1701-1703.

2003

High-performance liquid chromatographic assay of metabolites of thioguanine and mercaptopurine in capillary blood.
Erb N, Haverland U, Harms D, Escherich G, Janka-Schaub G
J CHROMATOGR B. 2003;796(1):87-94.

1995

[Intraspinal metastasis of stage I anaplastic Wilms tumor]
Wiegel T, Grzyska U, Schwarz R, Escherich G
STRAHLENTHER ONKOL. 1995;171(5):296-299.

Letzte Aktualisierung aus dem FIS: 20.12.2024 - 23:36 Uhr